157 related articles for article (PubMed ID: 35247438)
1. The redox modulatory effects of SP/NK1R system: Implications for oxidative stress-associated disorders.
Ebrahimi S; Alalikhan A; Aghaee-Bakhtiari SH; Hashemy SI
Life Sci; 2022 May; 296():120448. PubMed ID: 35247438
[TBL] [Abstract][Full Text] [Related]
2. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
[TBL] [Abstract][Full Text] [Related]
3. The Therapeutic Potential of Aprepitant in Glioblastoma Cancer Cells through Redox Modification.
Rezaei S; Assaran Darban R; Javid H; Hashemy SI
Biomed Res Int; 2022; 2022():8540403. PubMed ID: 35281606
[TBL] [Abstract][Full Text] [Related]
4. NK1R/5-HT1AR interaction is related to the regulation of melanogenesis.
Wu H; Zhao Y; Huang Q; Cai M; Pan Q; Fu M; An X; Xia Z; Liu M; Jin Y; He L; Shang J
FASEB J; 2018 Jun; 32(6):3193-3214. PubMed ID: 29430989
[TBL] [Abstract][Full Text] [Related]
5. The neurokinin-1 receptor in addictive processes.
Schank JR
J Pharmacol Exp Ther; 2014 Oct; 351(1):2-8. PubMed ID: 25038175
[TBL] [Abstract][Full Text] [Related]
6. Substance P promotes the recovery of oxidative stress-damaged retinal pigmented epithelial cells by modulating Akt/GSK-3β signaling.
Baek SM; Yu SY; Son Y; Hong HS
Mol Vis; 2016; 22():1015-23. PubMed ID: 27582624
[TBL] [Abstract][Full Text] [Related]
7. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
8. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
9. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
10. Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief.
Jensen DD; Lieu T; Halls ML; Veldhuis NA; Imlach WL; Mai QN; Poole DP; Quach T; Aurelio L; Conner J; Herenbrink CK; Barlow N; Simpson JS; Scanlon MJ; Graham B; McCluskey A; Robinson PJ; Escriou V; Nassini R; Materazzi S; Geppetti P; Hicks GA; Christie MJ; Porter CJH; Canals M; Bunnett NW
Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566424
[TBL] [Abstract][Full Text] [Related]
11. Substance P and the Neurokinin-1 Receptor: The New CRF.
Schank JR; Heilig M
Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150
[TBL] [Abstract][Full Text] [Related]
12. Substance P enhances the local activation of NK
Jeong YM; Cheng XW; Lee KH; Lee S; Cho H; Kim W
BMC Mol Cell Biol; 2020 Jun; 21(1):41. PubMed ID: 32517655
[TBL] [Abstract][Full Text] [Related]
13. Substance P excites GABAergic neurons in the mouse central amygdala through neurokinin 1 receptor activation.
Sosulina L; Strippel C; Romo-Parra H; Walter AL; Kanyshkova T; Sartori SB; Lange MD; Singewald N; Pape HC
J Neurophysiol; 2015 Oct; 114(4):2500-8. PubMed ID: 26334021
[TBL] [Abstract][Full Text] [Related]
14. The neuropeptide substance P/neurokinin-1 receptor system and diabetes: From mechanism to therapy.
Kokabi F; Ebrahimi S; Mirzavi F; Ghiasi Nooghabi N; Hashemi SF; Hashemy SI
Biofactors; 2023; 49(3):534-559. PubMed ID: 36651605
[TBL] [Abstract][Full Text] [Related]
15. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses.
Jafarinezhad S; Assaran Darban R; Javid H; Hashemy SI
Cell Biochem Biophys; 2023 Dec; 81(4):787-794. PubMed ID: 37740877
[TBL] [Abstract][Full Text] [Related]
16. Neurokinin 1 Receptor Antagonists for Pruritus.
Alam M; Buddenkotte J; Ahmad F; Steinhoff M
Drugs; 2021 Apr; 81(6):621-634. PubMed ID: 33675531
[TBL] [Abstract][Full Text] [Related]
17. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.
Spitsin S; Tuluc F; Meshki J; Ping Lai J; Tustin Iii R; Douglas SD
Neuroimmunomodulation; 2013; 20(5):247-55. PubMed ID: 23921645
[TBL] [Abstract][Full Text] [Related]
18. Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells.
Kepler CK; Markova DZ; Koerner JD; Mendelis J; Chen CM; Vaccaro AR; Risbud MV; Albert TJ; Anderson DG
Spine (Phila Pa 1976); 2015 Aug; 40(16):1261-9. PubMed ID: 25929203
[TBL] [Abstract][Full Text] [Related]
19. New insight into the role of substance P/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs.
Ebrahimi S; Javid H; Alaei A; Hashemy SI
Clin Genet; 2020 Oct; 98(4):322-330. PubMed ID: 32266968
[TBL] [Abstract][Full Text] [Related]
20. Neurokinin-1 receptor antagonism attenuates neuronal activity triggered by stress-induced reinstatement of alcohol seeking.
Schank JR; Nelson BS; Damadzic R; Tapocik JD; Yao M; King CE; Rowe KE; Cheng K; Rice KC; Heilig M
Neuropharmacology; 2015 Dec; 99():106-14. PubMed ID: 26188146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]